Get the Stockscreener App
5.94
1.98%
-0.12
After Hours:
5.93
-0.01
-0.17%
Gyre Therapeutics Inc stock is traded at $5.94, with a volume of 125.88K.
It is down -1.98% in the last 24 hours and down -20.16% over the past month.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
See More
Previous Close:
$6.06
Open:
$6.1
24h Volume:
125.88K
Relative Volume:
1.26
Market Cap:
$576.35M
Revenue:
$116.59M
Net Income/Loss:
$9.88M
P/E Ratio:
264.00
EPS:
0.0225
Net Cash Flow:
$-2.40M
1W Performance:
-5.11%
1M Performance:
-20.16%
6M Performance:
-24.33%
1Y Performance:
-31.57%
1-Day Range:
$5.87
$6.16
1-Week Range:
$5.87
$6.2935
52-Week Range:
$5.87
$11.61
Gyre Therapeutics Inc Stock (GYRE) Company Profile
Name
Gyre Therapeutics Inc
Sector
Industry
Phone
(858) 284-0115
Address
12730 HIGH BLUFF DRIVE, SAN DIEGO
Compare GYRE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GYRE
Gyre Therapeutics Inc
|
5.94 | 587.99M | 116.59M | 9.88M | -2.40M | 0.0225 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | Jefferies | Buy |
| Aug-26-25 | Initiated | H.C. Wainwright | Buy |
| Mar-11-25 | Initiated | Noble Capital Markets | Outperform |
| Apr-29-21 | Resumed | Stephens | Overweight |
| Feb-10-21 | Initiated | Piper Sandler | Overweight |
| May-21-20 | Initiated | Raymond James | Outperform |
| Jan-04-19 | Initiated | Oppenheimer | Outperform |
| Feb-12-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Feb-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Dec-08-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Jun-12-17 | Initiated | Chardan Capital Markets | Buy |
| Jun-06-17 | Initiated | Ladenburg Thalmann | Buy |
| Jun-30-16 | Initiated | Rodman & Renshaw | Buy |
View All
Gyre Therapeutics Inc Stock (GYRE) Latest News
GYRE Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline Amid Pre-Revenue Stage - Newser
Gyre therapeutics COO Ye Weiguo’s $136,653 stock sale - Investing.com
GYRE (GYRE) COO sells 22,220 shares after stock option exercises - Stock Titan
GYRE Stock Price, Quote & Chart | GYRE THERAPEUTICS INC (NASDAQ:GYRE) - ChartMill
Gyre Therapeutics (GYRE) director cancels 250,000-share stock option agreement - Stock Titan
Gyre Therapeutics COO Ye Weiguo sells $59,418 in shares - Investing.com
Gyre Therapeutics (GYRE) COO sells shares after exercising options - Stock Titan
Gyre Therapeutics (GYRE) Stock: Slides -2.17%, Support at $5.98 2026-05-19Advance Decline Volume - Newser
GYRE (GYRE) COO Ye exercises options and sells 28,680 shares in May - Stock Titan
Gyre Therapeutics (GYRE) Fell -6.43% — Is a Recovery Ahead? 2026-05-17Community Momentum Stocks - Newser
Gyre Therapeutics and Cullgen Advance CDK2-Cyclin E Degrader CG923308 for Treatment of Solid Tumors and CDK4/6i-Resistant Breast Cancer - Minichart
GYRE Should I Buy - Intellectia AI
Gyre Therapeutics Highlights Cullgen Acquisition and Pipeline Expansion - TipRanks
Gyre Therapeutics to present CG923308 data; expects IND submission Q1 2027 - TradingView
Gyre Therapeutics (NASDAQ: GYRE) showcases degrader pipeline and CG923308 IND plans - Stock Titan
Gyre Therapeutics stock (KYG4200L1031): Low short interest signals stability amid pharma peers - AD HOC NEWS
China regulator accepts Gyre’s liver fibrosis drug application By Investing.com - Investing.com India
Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (Hydronidone) to Treat CHB-Induced Liver Fibrosis - Minichart
Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment - The Manila Times
Gyre Therapeutics’ F351 NDA Accepted for Priority Review - TipRanks
Gyre Therapeutics announces NMPA acceptance of new drug application for F351 (hydronidone) - marketscreener.com
Gyre Therapeutics (GYRE) wins NMPA review acceptance for F351 liver fibrosis NDA - Stock Titan
GNI Group Reshapes Top Management as Gyre Advances Cullgen Acquisition - TipRanks
China regulator accepts Gyre’s liver fibrosis drug application - Investing.com India
New hepatitis B liver drug for China’s tens of millions enters NMPA review - Stock Titan
TradingKey - TradingKey
Number of shareholders of Gyre Therapeutics, Inc. – NASDAQ:GYRE - TradingView
[144] GYRE THERAPEUTICS, INC. SEC Filing - Stock Titan
Q2 EPS Forecast for Gyre Therapeutics Reduced by Analyst - MarketBeat
Noble Financial Sticks to Their Buy Rating for Gyre Therapeutics (GYRE) - The Globe and Mail
Gyre Therapeutics, Inc. 10-Q Quarterly Financial Report March 31, 2026 – Financial Statements, Risk Factors, and Disclosures - Minichart
Gyre Therapeutics (NASDAQ: GYRE) Q1 2026 results and $300M Cullgen deal - Stock Titan
Gyre Therapeutics stock (KY.G4200L1031): Acquisition of Cullgen and Q1 2026 results in focus - AD HOC NEWS
GYRE SEC FilingsGyre Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Noble Financial Maintains Gyre Therapeutics(GYRE.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Gyre Ramps Up F351 and Cullgen Investments as Q1 Swings to Loss - TipRanks
Gyre Therapeutics CEO Luo Ying sells $82,927 in company stock By Investing.com - Investing.com Nigeria
Gyre Therapeutics CEO Luo Ying sells $82,927 in company stock - Investing.com India
Gyre Therapeutics (GYRE) CEO spouse sells 10,315 shares under plan - Stock Titan
Gyre Therapeutics (GYRE) CSO discloses new Series B stake - Stock Titan
H.C. Wainwright Maintains Gyre Therapeutics(GYRE.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Gyre Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
GYRE STOCK ALERT: Kaskela Law Firm Announces Shareholder Investigation into Gyre Therapeutics, Inc. (GYRE) and Encourages Long-Term GYRE Shareholders to Contact the Firm - ACCESS Newswire
Gyre Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Gyre Therapeutics, Inc. (GYRE) reports Q1 loss, lags revenue estimates - MSN
Gyre Therapeutics, Inc. (GYRE) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Earnings Flash (GYRE) Gyre Therapeutics, Inc. Reports Q1 Revenue $22.5M, vs. FactSet Est of $31.6M - marketscreener.com
Earnings Flash (GYRE) Gyre Therapeutics Posts Q1 Loss $0.10 a Share, vs. FactSet Est of $0.07 Loss - marketscreener.com
Q1 2026 loss and Cullgen deal reshape Gyre Therapeutics (NASDAQ: GYRE) - Stock Titan
Gyre Therapeutics Q1 revenue rises 2% but misses analyst estimates - TradingView
Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update - The Manila Times
Gyre Therapeutics Inc Stock (GYRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Gyre Therapeutics Inc Stock (GYRE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ye Weiguo | Chief Operating Officer |
May 20 '26 |
Option Exercise |
0.75 |
9,400 |
7,050 |
709,400 |
| Ye Weiguo | Chief Operating Officer |
May 21 '26 |
Sale |
6.15 |
12,820 |
78,843 |
700,000 |
| Ye Weiguo | Chief Operating Officer |
May 20 '26 |
Sale |
6.15 |
9,400 |
57,810 |
700,000 |
| Ye Weiguo | Chief Operating Officer |
May 19 '26 |
Option Exercise |
0.75 |
9,120 |
6,840 |
709,120 |
| Ye Weiguo | Chief Operating Officer |
May 18 '26 |
Option Exercise |
0.75 |
200 |
150 |
700,200 |
| Ye Weiguo | Chief Operating Officer |
May 19 '26 |
Sale |
6.37 |
9,120 |
58,094 |
700,000 |
| Ye Weiguo | Chief Operating Officer |
May 18 '26 |
Sale |
6.62 |
200 |
1,324 |
700,000 |
| Ye Weiguo | Chief Operating Officer |
May 14 '26 |
Option Exercise |
0.75 |
15,580 |
11,685 |
715,580 |
| Ye Weiguo | Chief Operating Officer |
May 15 '26 |
Option Exercise |
0.75 |
13,100 |
9,825 |
713,100 |
| Ye Weiguo | Chief Operating Officer |
May 14 '26 |
Sale |
6.91 |
15,580 |
107,658 |
700,000 |
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):